<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To analyze the association of genetic variation within the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF -308 [G--&gt;A]) and lymphotoxin alfa (LT-a +252 [A--&gt;G]) genes with outcome in non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of childhood and adolescence </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Genotyping of the TNF -308 (G--&gt;A) and LT-a +252 (A--&gt;G) polymorphisms in patients (n = 488) enrolled onto the German-Austrian-Swiss multicenter trial NHL-BFM 95 from April 1996 to January 2000 was performed by polymerase chain reaction with subsequent restriction fragment length polymorphism analysis on DNA from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free specimen </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: In patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and B-cell <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>; n = 219, 211 eligible patients), patients carrying at least two variant alleles (high-producer haplotypes) had an increased risk of events: probability of event-free survival (pEFS) at 3 years was 81% (SE = 5%), compared with 91% (SE = 2%) in low-producer haplotypes (P = .018) </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> with high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load (<z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase [LDH] &gt; or = 500 U/L; n = 104), pEFS was 69% (SE = 8%) in high-producer versus 85% (SE = 4%) in low-producer haplotypes (P = .05) </plain></SENT>
<SENT sid="4" pm="."><plain>In multivariate analysis including risk factors for events (LDH &gt; or = 500 U/L, <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> infusion regimen), TNF -308/LT-alpha +252 haplotype kept prognostic relevance: patients with high-producer haplotypes had a 2.34-fold increase in risk of events (P = .048) </plain></SENT>
<SENT sid="5" pm="."><plain>The TNF -308 (G--&gt;A) and LT-alpha +252 (A--&gt;G) polymorphisms were not associated with pEFS in lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 101), anaplastic large-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 67), or diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 65), nor with therapy-related toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: The TNF -308 (G--&gt;A) and LT-a +252 (A--&gt;G) polymorphisms were negative prognostic factors in pediatric <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients with serum LDH &gt; or = 500 U/L, haplotype analysis further determined patients at risk for events </plain></SENT>
</text></document>